{'fraction_non_alphanumeric': 0.017834394904458598, 'fraction_numerical': 0.005095541401273885, 'mean_word_length': 5.834782608695652, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The use of IVIG in pediatric oncohematology and hematopoietic stem cell transplantation].

Intravenous immunoglobulins (IVIG) remain an important part of both causative and supportive therapy in pediatric oncohematology and after hematopoietic cell transplantation. The article presents actual recommendations on the use of IVIG based on personal experience and on UK guidelines published in 2008. IVIG substitution remains an important part of therapy in children with delayed immune reconstitution after hematopoietic stem cell transplantation (post transplants from alternative donors and in the course of acute and chronic Graft versus Host Disease). IVIG play a significant role in the immunomodulation of children with autoimmune disorders, i.e. primary immune thrombocytopenia.